SARS-CoV-2 Antiviral Prescribing Gaps Among Nonhospitalized High-Risk Adults

Clin Infect Dis. 2024 Jun 14;78(6):1531-1535. doi: 10.1093/cid/ciad796.

Abstract

Within a multistate clinical cohort, SARS-CoV-2 antiviral prescribing patterns were evaluated from April 2022-June 2023 among nonhospitalized patients with SARS-CoV-2 with risk factors for severe COVID-19. Among 3247 adults, only 31.9% were prescribed an antiviral agent (87.6% nirmatrelvir/ritonavir, 11.9% molnupiravir, 0.5% remdesivir), highlighting the need to identify and address treatment barriers.

Keywords: SARS-CoV-2; antiviral agents; electronic health records; molnupiravir; nirmatrelvir.

MeSH terms

  • Adenosine Monophosphate / analogs & derivatives
  • Adenosine Monophosphate / therapeutic use
  • Adult
  • Aged
  • Alanine / analogs & derivatives
  • Alanine / therapeutic use
  • Antiviral Agents* / therapeutic use
  • COVID-19 / epidemiology
  • COVID-19 Drug Treatment*
  • Cytidine / analogs & derivatives
  • Female
  • Humans
  • Hydroxylamines
  • Male
  • Middle Aged
  • Practice Patterns, Physicians' / statistics & numerical data
  • Risk Factors
  • Ritonavir / therapeutic use
  • SARS-CoV-2*

Substances

  • Antiviral Agents
  • remdesivir
  • Ritonavir
  • Adenosine Monophosphate
  • Alanine
  • molnupiravir
  • Cytidine
  • Hydroxylamines